Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SSGJ-707
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : $6,050.0 million
Deal Type : Licensing Agreement
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
Details : Under the agreement, 3SBio will grant Pfizer an exclusive global license to develop, manufacture and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, worldwide, excluding China.
Product Name : SSGJ-707
Product Type : Antibody
Upfront Cash : $1,250.0 million
May 19, 2025
Lead Product(s) : SSGJ-707
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : $6,050.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pegadricase
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Selecta Biosciences
Deal Size : $4.0 million
Deal Type : Licensing Agreement
Details : Selecta Biosciences, 3SBio partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of chronic refractory gout on behalf of SobiTM, and has made a milestone payment of USD 4 million to 3SBio.
Product Name : SEL-212
Product Type : Enzyme
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : Pegadricase
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Selecta Biosciences
Deal Size : $4.0 million
Deal Type : Licensing Agreement
Reset All
